SCHEMBL6663935

SCHEMBL6663935

COc1ccc(-c2sc3cc(OC)ccc3c2C(=O)c2ccc(OCCN3CCCC3)cc2)cc1

nearest known ligand 0.98

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 17/20 0.98
ESR2 Q92731 17/20 0.98
ENPP1 P22413 2/20 0.81
ENPP3 O14638 2/20 0.81
MEN1 O00255 2/20 0.76
ALDH1A1 P00352 2/20 0.76
LMNA P02545 2/20 0.76
TP53 P04637 2/20 0.76
CYP3A4 P08684 2/20 0.76
MAPT P10636 2/20 0.76
ALOX15 P16050 2/20 0.76
KMT2A Q03164 2/20 0.76
HSD17B10 Q99714 2/20 0.76
TDP1 Q9NUW8 2/20 0.76
PLD2 O14939 1/20 0.76
KDM1A O60341 1/20 0.76
NR1I2 O75469 1/20 0.76
USP2 O75604 1/20 0.76
C5 P01031 1/20 0.76
FYN P06241 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665661 0.99 ESR1 (1.00) ESR1ESR2ENPP1ENPP3MEN1
SCHEMBL6595860 0.99 ESR1 (0.96) ESR1ESR2ENPP1ENPP3MEN1
Bromide SCHEMBL1665326 0.98 ESR1 (0.98) ESR1ESR2ENPP1ENPP3MEN1
Hydrochloric Acid SCHEMBL2495864 0.98 ESR1 (1.00) ESR1ESR2ENPP1ENPP3MEN1
SCHEMBL7632970 0.98 ESR1 (0.98) ESR1ESR2ENPP1ENPP3MEN1
Hydrochloric Acid SCHEMBL1665332 0.98 ESR1 (1.00) ESR1ESR2ENPP1ENPP3MEN1
SCHEMBL7669007 0.95 ESR1 (0.89) ESR1ESR2ENPP1ENPP3MEN1
SCHEMBL7451142 0.95 ESR1 (0.89) ESR1ESR2ENPP1ENPP3MEN1
SCHEMBL11550698 0.94 ESR1 (1.00) ESR1ESR2MEN1ALDH1A1LMNA
SCHEMBL6597408 0.94 ESR1 (0.88) ESR1ESR2ENPP1ENPP3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0873051-B1 MODULATION OF CALCIUM CHANNELS LILLY CO ELI (US) 2004-08-04 EP disclosed
EP-0831822-B1 The use of calcium channel antagonists for treating cardiac, renal and gastrointestinal disorders and hypertension LILLY CO ELI (US) 2003-10-29 EP disclosed
EP-0831822-A4 CALCIUM CHANNEL ANTAGONISTS LILLY CO ELI (US) 2001-12-19 EP disclosed
EP-0873051-A4 MODULATION OF CALCIUM CHANNELS LILLY CO ELI (US) 1999-01-07 EP disclosed
EP-0873051-A1 MODULATION OF CALCIUM CHANNELS ELI LILLY AND COMPANY (US) 1998-10-28 EP disclosed
EP-0831822-A1 CALCIUM CHANNEL ANTAGONISTS ELI LILLY AND COMPANY (US) 1998-04-01 EP disclosed
WO-1996040134-A1 CALCIUM CHANNEL ANTAGONISTS ELI LILLY AND COMPANY (US) 1996-12-19 WO disclosed
WO-1996039833-A1 MODULATION OF CALCIUM CHANNELS ELI LILLY AND COMPANY (US) 1996-12-19 WO disclosed
US-5571808-A SUBSTITUTED 2-ARYL-3-AROYLBENZO(B)THIOPHENES ELI LILLY AND COMPANY (US) 1996-11-05 US disclosed
EP-0724881-A1 Method for treating smoking-related bone loss ELI LILLY AND COMPANY (US) 1996-08-07 EP disclosed
US-5532254-A CARDIOVASCULAR ELI LILLY AND COMPANY (US) 1996-07-02 US disclosed
US-4133814-A ANTITUMOR AGENTS ELI LILLY AND COMPANY (US) 1979-01-09 US disclosed